TAI LCx

Drug Profile

TAI LCx

Alternative Names: TAI-LCx; Turmeric anti-inflammatory - lipophilic compound x

Latest Information Update: 05 Nov 2015

Price : $50

At a glance

  • Originator University of Arizona
  • Developer Botanisol
  • Class Small molecules
  • Mechanism of Action Prostaglandin modulators; Tumour necrosis factor alpha modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 23 Oct 2015 Washington State University and Botanisol collaborate to co-develop TAI LCx for Inflammation
  • 15 Oct 2015 The University of Arizona has patent protection for TAI LCx related technology
  • 15 Oct 2015 TAI LCx is licensed to Botanisol
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top